Intersect ENT Reports Fourth Quarter and Full Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Intersect ENT (XENT) Tops Q4 EPS by 10c, Revenues Beat; Affirms FY20 Revenue Guidance Below Consensus
February 24, 2020 7:04 AM ESTIntersect ENT (NASDAQ: XENT) reported Q4 EPS of ($0.25), $0.10 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $31.8 million versus the consensus estimate of $31.19 million.
Fourth Quarter 2019 Overview
Net Sales of $31.8 million a decrease of 3% from prior year.Gross Profit and Margin of $24.5 million and 77%, respectively.Operating Expenses of $33.1 million.We are encouraged by... More
